WHAT IS CLAIMED IS:

- A method of reducing or inhibiting graft vs. host disease in a
 bone marrow transfer in a mammal, comprising administering to said mammal an effective amoiunt of interleukin-10.
- 2. A method of inhibiting, by an immune system, an antigen-specific response to subsequent presentation of said antigen, comprising administering to said immune system an effective amount of exogenous interleukin-10 and said antigen.
 - 3. The method of Claim 2:

15

25

- a) wherein said immune response is mediated by a macrophage, APC, langerhans cell, or dendritic cell;
- b) further inhibiting proliferative response of CD4+ hostreactive T cell clones; or
- c) wherein said inhibiting persists for at least about 21 days.
- 20 4. The method of Claim 2, wherein said effective amount is sufficient to decrease responder T cell activation.
 - 5. The method of Claim 4, further comprising reduced stimulatory capacity of peripheral blood mononuclear cells, dendritic cells, monocytes, and/or normal B cells.
 - 6. A substantially pure antigen-specific anergic T cell characterized by production upon restimulation of:
 - a) low IL-2;
 - b) low IL-4;
 - c) low IL-5;
 - d) intermediate IFN-γ;
 - e) low GM-CSF; and
 - f) high IL-10;
- 35 said population made by administering to precursors of said T cell with a combination of:

RONCAROLO, et al

- i) exogenous IL-10; and
- ii) antigen.
- 7. The anergic T cells of Claim 6:
 - a) wherein said precursors are CD4+ T cells;
 - b) which further produce high TNF- α ;
 - c) which induce an anergic response to said antigen;
 - d) wherein said IL-10 is human IL-10;
 - e) wherein said IL-10 is administered for at least about 7 days; or
 - f) wherein said anergic condition persists for at least about 21 days.
- 8. The population of Claim 6, wherein said antigen is selected from:
 - a) a protein antigen;
 - b) a particulate antigen;
 - c) an alloantigen; or
 - d) an autoantigen.

20

5

10

- 9. The population of Claim 8, wherein said antigen is selected from:
 - a) an alloantigen; or
 - b) an autoantigen.

25

- 10. A substantially pure antigen-specific anergic T cell characterized by production upon restimulation of:
 - a) low IL-2;
 - b) low IL-5;
 - c) intermediate IFN-γ;
 - d) low GM-CSF; and
 - e) high IL-10.
- 11. The anergic T cell of Claim 10, wherein said production of:
- 35 a) IL-2 is less than about 500 pg/ml;
 - b) IL-5 is between about 300 and 3000 pg/ml;

RONCAROLO, et al.

- c) IFN-γis at least about 1000 pg/ml;
- d) GM-CSF is about 300-3000 pg/ml; and
- e) IL-10 is at least about 3000 pg/ml.
- 5 12. The anergic T cell of Claim 11, wherein said IL-10 level upon restimulation is at least about 5x that of a Th1 cell.
 - 13. A substantially pure T cell which exhibits an antigen-specific anergy to an antigen.


- 14. The T cell of Claim 13:
 - a) wherein said antigen is an alloantigen or self antigen;
 - b) which produces IL-10 upon restimulation at least about 3000 pg/ml; or
- 15 c) which exhibits said antigen-specific anergy for at least about 21 days.
- - a) exogenous IL-10; and
 - b) either antigen or anti-CD3 antibodies.
- 16. The method of Claim 15, wherein said antigen is alloantigen or self antigen.
 - 17. The method of Claim 16, wherein said antigen is restricted by MHC molecules.
- 30 18. The method of Claim 15, performed in vivo.
 - 19. The method of Claim 15, which further suppresses response to subsequent stimulation.
- 35 20. The method of Claim 19, wherein said response accompanies tissue transplantation.

10

15

30

- 21. The method of Claim 20, wherein said tissue is an organ or bone marrow.
- 5 22. The method of Claim 20, wherein said T cell is from the recipient of said tissue transplantation.
 - 23. The method of Claim 15, wherein said response accompanies tissue transplantation and:
 - a) said administering is prior to said tissue transplantation;
 - b) said T cell is introduced to the recipient of said tissue transplantation; or
 - c) IL-10 is administered to the tissue to be transplanted before said transplantation.
- 24. The method of Claim 16, wherein said antigen causes an autoimmune disease.
- 25. A method of suppressing a subsequent response in a T cell to an antigen, comprising administering to an immune system comprising said cell with a combination of:
 - a) exogenous IL-10; and
 - b) either antigen or anti-CD3 antibodies.
- 25 26. The method of Claim 25, wherein said IL-10 is administered for at least about 7 days.
 - 27. A method of inducing in a T cell anergy to an MHC antigen, comprising administering to a precurser to said T cell:
 - a) exogenous IL-10 and said antigen; or
 - b) exogenous IL-10 with anti-CD3.
 - 28. The method of Claim 27, wherein said administering with IL-10 is for at least about 7 days.
 - 29. A composition comprising IL-10 and antigen.



- 30. The composition of Claim 29, wherein:
 - said composition is a pharmaceutical composition comprising said IL-10 and a pharmaceutically acceptable carrier;
 - said IL-10 is human IL-10; or b)
 - said antigen is selected from the group consisting of:
 - alloantigen;
 - ii) self antigen;
 - iii) protein antigen; and
- iv) particulate antigen. 10